AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06488898
Drug: Allogeneic adipose tissue-derived mesenchymal stem cells
RxNorm normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational medicinal product: Allogeneic adipose tissue-derived mesenchymal stem cells and expanded, which are considered an advanced therapy medicinal product under European regulation (Article 2(1) of Regulation (EC) No 1394/2007 of the European Parliament and the Council of November 13 th 2007 about advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004).~Administration form: Local injection by means of a catheter placed inside the previously excluded aneurysmal sac.~Administration dose: 1x10000000 cells/kg patient weight.~Administration guidelines: single infusion on the endovascular day AAA intervention.
Trial: NCT05127122
Drug: Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles
RxNorm normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable
Trial: NCT00002168
Drug: Indinavir sulfate
RxNorm normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002168
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00002168
Drug: Stavudine
RxNorm normalized name: Stavudine
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002168
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002168
Drug: Didanosine
RxNorm normalized name: Didanosine
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04369547
Drug: Roflumilast
RxNorm normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Roflumilast 250mcg
Trial: NCT05100303
Drug: Mitoxantrone Hydrochloride liposome injection
RxNorm normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitoxantrone hydrochloride liposome will be administered by intravenous (IV) injections.
Trial: NCT05100303
Drug: Cytarabine (LoDAC)
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose or high-dose cytarabine (LoDAC) will be administered by intravenous (IV) injections.
Trial: NCT04408664
Drug: Sodium Cromoglycate
RxNorm normalized name: Sodium cromoglycate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium Cromoglicate 10 mg/mL packed in ampulla of 2 mL; Daily dosis of 4X20 mg milligram delivered by aerosol.
Trial: NCT00992654
Drug: Open Label Treatment Access: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dosing twice daily. The dose will depend on the optimized background therapy.
Trial: NCT04714190
Drug: RC48-ADC
RxNorm normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5 mg/kg IV every 2 weeks
Trial: NCT04714190
Drug: Paclitaxel injection
RxNorm normalized name: paclitaxel Injection
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered according to label, as one option for Physician's Choice (determined before randomization)
Trial: NCT04714190
Drug: Irinotecan Hydrochloride Injection
RxNorm normalized name: Irinotecan Hydrochloride Injection
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered according to label, as one option for Physician's Choice (determined before randomization)
Trial: NCT04714190
Drug: Apatinib Mesylate Tablets
RxNorm normalized name: mesylate
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered according to label, as one option for Physician's Choice (determined before randomization)
Trial: NCT03968913
Drug: Anakinra injection
RxNorm normalized name: anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: anakinra 150mg in 5milliliters of sterile saline will be injected into the knee joint
Trial: NCT04668209
Drug: Silmitasertib
RxNorm normalized name: Silmitasertib
DrugBank: Silmitasertib (DB15408)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care / best supportive care in combination with CX-4945 1000 mg administered orally, two times a day.
Trial: NCT05951361
Drug: 0.1% topical triamcinolone Acetonide preparation Kenacourt-A Orabase
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: three times daily for 4 weeks
Trial: NCT02953496
Drug: vonapanitase
RxNorm normalized name: Vonapanitase
DrugBank: Vonapanitase (DB11690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vonapanitase will be administered to the target lesion of the SFA or PA via percutaneous needle injection under ultrasound guidance.
Trial: NCT06452602
Drug: Induction immunochemotherapy followed by Adebrelimab plus concurrent chemoradiotherapy
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction immunochemotherapy:~Nab-paclitaxel：220mg/m2，IV，d1，d22; Carboplatin：AUC=5，IV，d1，d22; Adebrelimab：1200mg, IV，d1, d22.~Evaluation of the Curative Effect：CR+PR~Adebrelimab plus concurrent chemoradiotherapy:~Adebrelimab：1200mg, IV，q3w, until PD; Nab-paclitaxel：175mg/m2，IV，d1，d22; Carboplatin：AUC=5，IV，d1，d22; Radiotherapy：50.4Gy/1.8Gy/28f.
Trial: NCT01351090
Drug: Ketorolac tromethamine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg Intranasal (2 x 100 uL of a 5% solution)
Trial: NCT01351090
Drug: Ketorolac tromethamine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg Intranasal (2 x 100 uL of a 15% solution)
Trial: NCT00002182
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol acetate (DB00351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06300099
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone as adjunct to serratus anterior plane block.
Trial: NCT06300099
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine as adjunct to serratus anterior plane block.
Trial: NCT05419297
Drug: Buprenorphine Buccal Film [Belbuca]
RxNorm normalized name: buprenorphine Buccal Film [Belbuca]
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: buprenorphine buccal film is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Trial: NCT05335655
Drug: Dexmedetomidine injection
RxNorm normalized name: dexmedetomidine Injection
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV initial bolus and trans operative dexmedetomidine infusion.
Trial: NCT05335655
Drug: Sodium Chloride 0.9% infusion
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV initial bolus and trans operative infusion of 0.9% saline solution.
Trial: NCT00089518
Drug: Valsartan
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT06101147
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: These patients will receive Vitamin D3 1000 I.U daily and the Metformin as prescribed by the physician for 8 weeks.
Trial: NCT04871152
Drug: OnabotulinumtoxinA
RxNorm normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: To compare the effectiveness of triptans before and after initiation of treatment with OnabotuliumtoxinA.
Trial: NCT00939926
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT05141071
Drug: Ivabradine 5mg Tab
RxNorm normalized name: IVABRADINE 5MG TAB
DrugBank: Ivabradine (DB09083)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ivabradine will be administrated enterally
Trial: NCT05219604
Drug: DiphenhydrAMINE Injectable Solution
RxNorm normalized name: diphenhydramine Injectable Solution
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of diphenhydramine 50 mg.
Trial: NCT00443222
Drug: Infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT05600998
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive carilizumab every three weeks, with alozantinib 20 mg orally daily for 9 weeks
Trial: NCT06593834
Drug: BAT
RxNorm normalized name: RibaTab
DrugBank: Equine Botulinum Neurotoxin E Immune FAB2 (DB13897)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAT
Trial: NCT04262193
Drug: Suvorexant
RxNorm normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In each group, the participant will take 1 tablet (placebo or 20mg) 30 minutes before bedtime.
Trial: NCT04262193
Drug: Suvorexant Placebo
RxNorm normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Suvorexant Placebo
Trial: NCT06607796
Drug: Toluenesulfonamide (PTS) Intratumoral Injection
RxNorm normalized name: o-toluenesulfonamide
DrugBank: Toluene (DB11558)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intratumoral injection of toluenesulfonamide(PTS) to oligo lesions
Trial: NCT05942573
Drug: Serplulimab+Paclitaxel+Apatinib
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Immunotherapy+chemotherapy
Trial: NCT05942573
Drug: Paclitaxel±Ramucirumab
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: chemotherapy±Targeted therapy
Trial: NCT05023941
Drug: Acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Start orally take acetazolamide 125mg twice daily, 2 days before entering the hypoxic chamber. Subjects will enter the hypoxic room at 9am on the third day. At that time, the subject should have taken the drug 5 times.
Trial: NCT05076877
Drug: Lazertinib
RxNorm normalized name: Lazertinib
DrugBank: Lazertinib (DB16216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lazertinib tablets will be administered orally, alone or in combination with probe substrates.
Trial: NCT05076877
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam (cytochrome P450 3A4 \[CYP3A4\] substrate) will be administered orally as a syrup as a part of probe substrates.
Trial: NCT05076877
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (organic cation transporter 1 \[OCT1\] substrate) will be administered orally as a syrup as a part of probe substrates.
Trial: NCT06730750
Drug: BMS-986490
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified dose on specified days.
Trial: NCT06730750
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Specified dose on specified days.
Trial: NCT06490081
Drug: Trilaciclib
RxNorm normalized name: Trilaciclib
DrugBank: Trilaciclib (DB15442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During concurrent chemoradiotherapy in limited-stage small cell lung cancer, Trilaciclib is administered prophylactically before the first cycle of chemotherapy
Trial: NCT06437509
Drug: BL-B01D1
RxNorm normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Trial: NCT06437509
Drug: PD-1 monoclonal antibody
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Trial: NCT05655689
Drug: Moxifloxacin Ophthalmic 0.5% Ophthalmic Solution
RxNorm normalized name: moxifloxacin ophthalmic 0.5% ophthalmic solution
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the observational study, patients treated with topical antibiotic moxifloxacin 0.5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
Trial: NCT05655689
Drug: Ceftazidime 5% + vancomycin 5%
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the observational study, patients treated with topical fortified antibiotics ceftazidime 5% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
Trial: NCT05655689
Drug: Natamycin 5% Oph Susp
RxNorm normalized name: NATAMYCIN 5% OPH SUSP
DrugBank: Natamycin (DB00826)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the observational study, patients treated with the topical natamycin 5% antifungal eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
Trial: NCT05655689
Drug: Voriconazole 1%
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the observational study, patients treated with voriconazole 1% antifungal eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
Trial: NCT05655689
Drug: Natamycin 5% + voriconazole 1%
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the observational study, patients treated with the topical natamycin 5% and voriconazole 1% antifungals eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
Trial: NCT05655689
Drug: Natamycin 5%+ ceftazidime 5% + vancomycin 5%
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the observational study, patients treated with the topical natamycin 5% and antifungal and the fortified antibiotic ceftazidime 5% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
Trial: NCT05655689
Drug: Voriconazole 1% + ceftazidime 5% + vancomycin 5%
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the observational study, patients treated with the topical voriconazole 1% antifungal and the fortified antibiotics ceftazidime 5% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
Trial: NCT05041803
Drug: CTP-543
RxNorm normalized name: CTP-SOMATROPIN FUSION PROTEIN
DrugBank: Somatrogon (DB14960)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Twice daily dosing
Trial: NCT05201326
Drug: Bevacizumab，Irinotecan and Re-radiotherapy
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All patients with recurrent glioblastoma will accept irinotecan and bevacizumab combined with re-radiotherapy .
Trial: NCT05593653
Drug: Suvorexant
RxNorm normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mg taken at bedtime for 4 weeks
Trial: NCT06136455
Drug: Listerine Clinical Solutions Teeth Strength
RxNorm normalized name: SODIUM FLUORIDE 0.1 mg in 1 mL ORAL MOUTHWASH [Listerine Clinical Solutions Teeth Strength Alpine Mint]
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Clinical Solutions Teeth Strength mouthwash.
Trial: NCT06136455
Drug: Colgate Cavity Protection Toothpaste
RxNorm normalized name: Colgate
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will brush for 1 timed minute with Colgate Cavity Protection toothpaste.
Trial: NCT06765317
Drug: Glofitamab
RxNorm normalized name: Glofitamab
DrugBank: Glofitamab (DB16371)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C1D8 2.5 mg iv; C1D15 10 mg iv; C2D1-onwards: 30 mg iv, every 3 weeks
Trial: NCT06765317
Drug: Polatuzumab
RxNorm normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1.8 mg/kg iv C1D1 onwards, every 3 weeks
Trial: NCT06501807
Drug: Biologic treatments available in Chronic Rhinosinusitis with Nasal Polyps (dupilumab, mepolizumab and benralizumab according to their marketing approval).
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug prescription according to their marketing approval (subcutaneously, every month or every two weeks).
Trial: NCT06765317
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375 mg/m2 iv D1
Trial: NCT06765317
Drug: Obinutuzumab:
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1000 mg iv C1D1 (7 days prior to glofitamab administration) single dose
Trial: NCT05118620
Drug: Active bupivacaine 0.375% PENG block
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A PENG block with bupivacaine 0.375% and epinephrine will be administered using ultrasound-guidance
Trial: NCT06161714
Drug: Articaine 4%/Epi 1:100000 Inj Cart 1.7Ml
RxNorm normalized name: ARTICAINE 4%/EPI 1:100000 INJ CART 1.7ML
DrugBank: Articaine (DB09009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4% articaine with 1:100,000 epinephrine buccal infiltration
Trial: NCT06161714
Drug: Lidocaine 2%/Epi 1:100000 Inj Cart 1.7Ml
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2% Lidocaine with 1:100,000 epinephrine buccal infiltration
Trial: NCT04727736
Drug: 18F-DCFPyL
RxNorm normalized name: 18F-DCFPyL
DrugBank: Piflufolastat F 18 (DB14805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18F-DCFPyL (single dose injection) - a radiolabeled prostate-specific membrane antigen (PSMA) ligand
Trial: NCT04464967
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: HER2 receptor antagonistic, humanized immunoglobulin G subclass 1 (IgG1) monoclonal antibody
Trial: NCT04464967
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: EGFR antagonist, chimeric immunoglobulin G subclass 1 (IgG1) monoclonal antibody
Trial: NCT04993872
Drug: Biktarvy Tab
RxNorm normalized name: Biktarvy
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Multicenter Pilot study aiming to assess the safe use of BIC/FTC/TAF in HIV-KTR, using a single-arm design.
Trial: NCT05477004
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A multi-day continuous ketamine infusion delivered intravenously at subanesthetic doses in a monitored setting
Trial: NCT05587894
Drug: Paxlovid 5 days
RxNorm normalized name: nirmatrelvir
DrugBank: Nirmatrelvir (DB16691)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nirmatrelvir/r 300mg/100 mg bid will be given for 5 days, orally.~Nirmatrelvir/r is a combination of two molecules: nirmatrelvir which is a protease inhibitor (against 3CL) and ritonavir which has a booster role.~Nirmatrelvir/r (marketed by Pfizer under the brand name Paxlovid®) is indicated for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19.
Trial: NCT05587894
Drug: Paxlovid 10 days
RxNorm normalized name: nirmatrelvir
DrugBank: Nirmatrelvir (DB16691)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nirmatrelvir/r 300mg/100 mg bid will be given for 10 days, orally.
Trial: NCT05587894
Drug: Veklury
RxNorm normalized name: Veklury
DrugBank: Remdesivir (DB14761)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remdesivir flash, 200mg, intravenous. Remdesivir (marketed by Gilead under de brand name Veklury®) is indicated in patients with pneumonia requiring supplemental oxygen (inpatients), as well as in outpatients who are at increased risk of progressing to severe COVID-19. The mode of action characterize remdesivir as a direct-acting antiviral compound.
Trial: NCT04655508
Drug: Seretide
RxNorm normalized name: seractide
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: For children between 6 to 11 years (\< 12 years): 50 μg inhaled fluticasone propionate and 25 μg salmeterol (SERETIDE® 50/25) :two puffs twice a day from randomisation during 6 months using inhalation chamber~- For children between 12 to 17 years (\> or = 12 years) : 125 μg inhaled fluticasone propionate and 25 μg salmeterol (SERETIDE® 125/25): two puffs twice a day from randomisation during 6 months using inhalation chamber
Trial: NCT04531748
Drug: Toremifene
RxNorm normalized name: Toremifene
DrugBank: Toremifene (DB00539)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be instructed to take 60mg of oral toremifene capsule daily, 30 minutes before bedtime.
Trial: NCT05184348
Drug: Acitretin group
RxNorm normalized name: Acitretin
DrugBank: Acitretin (DB00459)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dose of 0.5-1 mg per kg per day orally for 3 month.
Trial: NCT05128591
Drug: Rivaroxaban 18mg Oral Tablet
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: AD-109 (Rivaroxaban 18mg) Oral Tablet